troglitazone has been researched along with Coronary Disease in 7 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Insulin resistance is associated with atherogenic lipoprotein phenotype, including small dense LDL particle, hypertriglycemia and low HDL cholesterol levels." | 6.69 | Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. ( Daida, H; Mokuno, H; Ohmura, H; Sawano, M; Shimada, K; Sunayama, S; Watanabe, Y; Yamaguchi, H, 1999) |
| " Recent studies demonstrated that hypoglycemic agents improving insulin resistance such as metformin and troglitazone reduce blood pressure." | 4.79 | [Treatment of hypertension associated with diabetes mellitus]. ( Katayama, S, 1997) |
| "Insulin resistance is associated with atherogenic lipoprotein phenotype, including small dense LDL particle, hypertriglycemia and low HDL cholesterol levels." | 2.69 | Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. ( Daida, H; Mokuno, H; Ohmura, H; Sawano, M; Shimada, K; Sunayama, S; Watanabe, Y; Yamaguchi, H, 1999) |
| "Dyslipoproteinemia associated with type 2 diabetes comprises hypertriglyceridemia caused by reduced insulin sensitivity, and consequently, low HDL levels and an increase in the proportion of small dense LDL particles." | 1.31 | [Diabetic dyslipoproteinemia: physiopathological bases and treatment prospects]. ( Demant, T, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Turner, NA | 1 |
| Mughal, RS | 1 |
| Warburton, P | 1 |
| O'Regan, DJ | 1 |
| Ball, SG | 1 |
| Porter, KE | 1 |
| Katayama, S | 1 |
| Howard, BV | 1 |
| Howard, WJ | 1 |
| Sunayama, S | 1 |
| Watanabe, Y | 1 |
| Ohmura, H | 1 |
| Sawano, M | 1 |
| Shimada, K | 1 |
| Mokuno, H | 1 |
| Daida, H | 1 |
| Yamaguchi, H | 1 |
| Takagi, T | 1 |
| Akasaka, T | 1 |
| Yamamuro, A | 1 |
| Honda, Y | 1 |
| Hozumi, T | 1 |
| Morioka, S | 1 |
| Yoshida, K | 1 |
| Marx, N | 1 |
| Hombach, V | 1 |
| Demant, T | 1 |
2 reviews available for troglitazone and Coronary Disease
| Article | Year |
|---|---|
[Treatment of hypertension associated with diabetes mellitus].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cerebrovascular Disorders; Chroma | 1997 |
[Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells].
Topics: Animals; Arteriosclerosis; Chromans; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, | 2001 |
2 trials available for troglitazone and Coronary Disease
| Article | Year |
|---|---|
Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance.
Topics: Aged; Chromans; Coronary Disease; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Hypogly | 1999 |
Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study.
Topics: Cell Division; Chromans; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; | 2000 |
3 other studies available for troglitazone and Coronary Disease
| Article | Year |
|---|---|
Mechanism of TNFalpha-induced IL-1alpha, IL-1beta and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones.
Topics: Analysis of Variance; Antibodies, Monoclonal; Cells, Cultured; Chromans; Coronary Disease; Dose-Resp | 2007 |
LDL cholesterol and troglitazone therapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Chromans; Coronary Disease; Diabetes Mellitus, Type 2; Hu | 1998 |
[Diabetic dyslipoproteinemia: physiopathological bases and treatment prospects].
Topics: Anticholesteremic Agents; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Chromans; Clinical Tria | 2001 |